Auna 3Q26 Conference Call - AUNA SA
Financial Performance:
- Total revenue grew 10% year-over-year on an FX-neutral basis.
- Consolidated free cash flow surged 95% year-to-date to S/626 million; net operating cash flow rose 62% to S/713 million.
- Leverage ratio improved sequentially to 3.5x net debt/EBITDA, trending toward a medium-term target of 3.0x.
- Adjusted EBITDA declined due to extraordinary items: Colombia faced S/40 million in adverse oncology costs (approx. 4% of revenue) and Peru absorbed S/18 million in prior-year billing adjustments. Excluding these, Peru's EBITDA remained stable and Mexico's grew 5%.
- Adjusted net income decreased primarily due to the absence of a S/40 million non-cash FX gain recorded in Q3 2025; underlying net finance costs improved to a blended rate of 10.38%.
- Capital expenditures remained at 3% of revenue, below the 4% full-year guidance.
- Cash conversion cycle improved from negative 9 days in 2025 to negative 15 days.
Guidance and Future Outlook:
- Full-year 2026 revenue growth guidance remains 10% to 14% (FX-neutral).
- Full-year 2026 adjusted EBITDA guidance remains broadly stable or slightly down year-over-year, reflecting one-off Colombia oncology costs and ongoing regulatory price cap impacts.
- Capex guidance remains unchanged at approximately 4% of consolidated revenues.
- Peru profitability is expected to improve in the second half of 2027 as billing reconciliations normalize and new B2B account utilization levels off.
- Mexico is projected to continue accelerating growth and margin expansion in Q4 and beyond.
- Colombia is expected to gradually recover profitability once the terminated contract is fully off-book and price cap impacts stabilize.
Business Segments and Product Lines:
- Mexico: Surgery volumes up 12% and oncology sessions (chemo/radio) up 34%; EBITDA grew 5% YoY despite industry-wide VAT deductibility headwinds. AUNA Seguros faced headwinds, but the Monterrey healthcare network grew EBITDA 10%.
- Peru: Surgery volumes up 21% and chemo/radio up 18%; EBITDA declined 6% excluding billing penalties. OncoSalud MLR stands at 50.7%. New corporate agreements will add 4,000 members in Q4.
- Colombia: Revenue grew 12% in local currency; EBITDA declined 30% due to an unprofitable oncology risk-sharing contract (terminated) and regulatory price caps on high-cost medications. Private payer revenues increased 22%.
- Strategic Initiatives: Expansion of high-complexity care (neurosurgery, orthopedics, cardiovascular) in Peru; Centro Ambulatorio Treca construction in Peru is on schedule.
- B2G Partnerships: Active progress on a potential partnership with SOGIE (Peru) and the Torre Treca public-private project.
Market and Competitive Landscape:
- Mexico's insurance market faced a 15-year low in policyholders due to VAT regulations, yet AUNA gained market share by offering competitive pricing to insurers.
- Colombia faces structural pressure from statutory wage increases and regulatory price caps, driving a strategic shift toward private payers and high-complexity care.
- Peru remains focused on high-margin B2B corporate accounts and asset-light expansion to increase capacity without heavy capital expenditure.
- AUNA continues to leverage its integrated model to capture high-complexity care volumes across the region.
Risks and Challenges:
- Colombia: Specific oncology risk-sharing contract incurred costs far exceeding assumptions (4% of revenue); regulatory price caps on oncology drugs impacting margins into Q4.
- Peru: Ongoing reconciliation of prior-year receivables affecting near-term earnings; high operational costs due to hospitalization and emergency volumes.
- Regulatory: Price caps in Colombia and VAT deductibility changes in Mexico.
- Environmental: Potential impact of a strong "El Niño" phenomenon; operational continuity plans activated for infrastructure and supply chain.
- Financial: FX exposure and debt maturity profiles (S/481m due in 12 months, well-covered by credit lines and cash).
Management Commentary and Tone:
- Management acknowledged a "tough quarter" with extraordinary, unexpected headwinds in Colombia and Peru but emphasized strong underlying fundamentals.
- Tone is confident regarding long-term regional potential, specifically highlighting Mexico's momentum and the strategic pivot in Colombia.
- Executives emphasized a commitment to predictability and controlling qualitative results to eliminate "surprises" for investors.
- Highlighted successful risk mitigation, such as the termination of the problematic Colombia contract and the robust response to the Pope's visit in Peru as a testament to operational capability.
Analyst Questions and Answers:
- Colombia Contract: Management confirmed the adverse oncology contract was an isolated incident with no expected contagion to other PGP/PIP contracts; the contract has been terminated.
- Mexico Utilization: Target utilization growth is projected at 2-3% annually; Monterrey network operates at 41% utilization with EBITDA margins of 28%, with room for further expansion.
- Peru Billing: Management expects billing reconciliation impacts to normalize by the second half of 2027 following improved internal billing cycles.
- El Niño: Specific contingency plans activated for fuel, water, power, and patient flow continuity across the Peru network.
- Bond Maturity: Approximately $100 million of 2029 bonds outstanding; callable at 105% at year-end, with refinancing options under constant review.
Other Key Points:
- AUNA Seguros in Mexico is pivoting to focus on B2B dental/vision and potential oncology insurance products.
- The company successfully managed the Pope's visit in Peru, demonstrating high-capacity operational readiness.
- 80% of Mexico's payer relationships have confirmed operating tiers; out-of-pocket revenue share is growing from 6% to ~9%.
- 54% of gross debt is in local currency, with 85% of USD-denominated debt hedged against the Sol and 75% of Mexican floating debt hedged.
- The "asset-light" strategy is being aggressively pursued in Peru and Colombia to expand high-complexity outpatient services.
- Company
- AUNA SA
- Keywords
- AUNA SA